Cullinan Therapeutics, Inc. CGEM Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $75.08M-15.0% | $88.33M-14.5% | $103.34M+41.9% | $72.82M-5.0% | $76.66M-7.7% | ||
| $276.8M-4.4% | $289.56M+26.3% | $229.26M+19.0% | $192.66M-15.2% | $227.17M-28.1% | ||
| $38.45M-10.3% | $42.87M-13.7% | $49.7M-8.0% | $54.03M-8.3% | $58.9M+2.1% | ||
| $361.41M-6.6% | $386.76M+13.0% | $342.24M+24.0% | $275.91M-13.2% | $317.77M-23.4% | ||
| $342K-18.8% | $421K-13.9% | $489K-14.1% | $569K-6.3% | $607K-11.1% | ||
| $2.44M-7.3% | $2.63M+151% | $1.05M-11.4% | $1.18M-23.9% | $1.55M-7.0% | ||
| $297K0.0% | $297K-17.7% | $361K-1.6% | $367K+0.3% | $366K0.0% | ||
| $38.5M-33.9% | $58.27M-58.4% | $140M-42.2% | $242.3M— | —— | ||
| $402.98M-10.1% | $448.37M-7.4% | $484.13M-7.0% | $520.33M-10.2% | $579.68M-6.8% | ||
| $7.53M-10.6% | $8.43M-9.1% | $9.27M-4.1% | $9.66M+10.4% | $8.75M-3.4% | ||
| $31.92M-11.6% | $36.12M+21.0% | $29.85M+23.3% | $24.2M+7.1% | $22.6M-18.3% | ||
| $725K-7.1% | $780K-34.3% | $1.19M-14.8% | $1.39M+3.5% | $1.35M+3.5% | ||
| $35.15M-6.9% | $37.74M+15.2% | $32.76M+16.7% | $28.06M+2.6% | $27.35M-10.8% | ||
| $1.66M-12.9% | $1.9M— | $0-100% | $125K-74.6% | $493K-41.9% | ||
| $2.38M-11.2% | $2.68M+126% | $1.19M-21.8% | $1.52M-17.4% | $1.84M-14.5% | ||
| $36.81M-7.1% | $39.64M+21.0% | $32.76M+16.2% | $28.18M+1.2% | $27.84M-11.6% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | ||
| $1B+0.8% | $995.82M+0.8% | $987.8M+1.0% | $978.33M+1.1% | $968.07M+1.0% | ||
| -$637.78M-8.4% | -$588.12M-9.4% | -$537.41M-10.4% | -$486.8M-16.8% | -$416.74M-13.2% | ||
| $127K-87.5% | $1.02M+4.8% | $973K+60.3% | $607K+20.2% | $505K+480% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $408.73M-9.4% | $451.37M-8.3% | $492.15M-10.8% | $551.84M-6.5% | ||
| $402.98M-10.1% | $448.37M-7.4% | $484.13M-7.0% | $520.33M-10.2% | $579.68M-6.8% | ||
| $297K0.0% | $297K-17.7% | $361K-1.6% | $367K+0.3% | $366K0.0% | ||
| $2.44M-7.3% | $2.63M+151% | $1.05M-11.4% | $1.18M-23.9% | $1.55M-7.0% | ||
| $38.5M-33.9% | $58.27M-58.4% | $140M-42.2% | $242.3M— | —— | ||
| $2.44M-7.3% | $2.63M+151% | $1.05M-11.4% | $1.18M-23.9% | $1.55M-7.0% | ||
| $297K0.0% | $297K-17.7% | $361K-1.6% | $367K+0.3% | $366K0.0% | ||
| $276.8M-4.4% | $289.56M+26.3% | $229.26M+19.0% | $192.66M-15.2% | $227.17M-28.1% | ||
| $2.44M-7.3% | $2.63M+151% | $1.05M-11.4% | $1.18M-23.9% | $1.55M-7.0% | ||
| $297K0.0% | $297K-17.7% | $361K-1.6% | $367K+0.3% | $366K0.0% | ||
| $31.92M-11.6% | $36.12M+21.0% | $29.85M+23.3% | $24.2M+7.1% | $22.6M-18.3% | ||
| $31.92M-11.6% | $36.12M+21.0% | $29.85M+23.3% | $24.2M+7.1% | $22.6M-18.3% | ||
| $2.38M-11.2% | $2.68M+126% | $1.19M-21.8% | $1.52M-17.4% | $1.84M-14.5% | ||
| $1B+0.8% | $995.82M+0.8% | $987.8M+1.0% | $978.33M+1.1% | $968.07M+1.0% | ||
| $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $9.52M+7.5% | $8.86M-8.1% | $9.64M-7.6% | $10.43M-25.2% | $13.95M-11.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cullinan Therapeutics, Inc.'s total assets?
- Cullinan Therapeutics, Inc. (CGEM) holds $403.0M in total assets, down 30.5% year over year.
- How much cash does Cullinan Therapeutics, Inc. have?
- Cullinan Therapeutics, Inc. holds $75.1M in cash and equivalents.
- Can Cullinan Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 10.28 — current assets exceed current liabilities.
- Where does Cullinan Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.